Fibroblastic rheumatism treated with methotrexate and colchicine
Beyond Rheumatology 2023;
5 (2): e477
DOI: 10.53238/br_20237_477
Topic: Dermatoarthropathy
Category: Case Report
Abstract
Objective: Fibroblastic rheumatism (FR) is a rare disease first described by Chaouat in 1980 which is characterized by a combination of rheumatologic and dermatological manifestations. Rheumatologic features are symmetrical polyarthralgia with joint stiffness, associated with cutaneous nodules and sclerodactyly. Histology shows an increased number of fibroblasts and marked dermal fibrosis. In this report, we described a rare cutaneous disease-fibroblastic rheumatism, in which the patient had an excellent response to methotrexate associated with colchicine.
Case Presentation: A 13 years old boy who was previously healthy started in 2013 deformities over his fingers without pain or any inflammatory signs associated with joint stiffness. This is the second Brazilian case of FR treated with methotrexate and colchicine.
Conclusions: The patient observed a slight improvement in cutaneous nodules and joint stiffness. Though FR is a rare disease, early diagnosis is mandatory. This case reinforces that MTX associated with colchicine may be an additional therapeutic tool for these patients.
Case Presentation: A 13 years old boy who was previously healthy started in 2013 deformities over his fingers without pain or any inflammatory signs associated with joint stiffness. This is the second Brazilian case of FR treated with methotrexate and colchicine.
Conclusions: The patient observed a slight improvement in cutaneous nodules and joint stiffness. Though FR is a rare disease, early diagnosis is mandatory. This case reinforces that MTX associated with colchicine may be an additional therapeutic tool for these patients.
To cite this article
Fibroblastic rheumatism treated with methotrexate and colchicine
Beyond Rheumatology 2023;
5 (2): e477
DOI: 10.53238/br_20237_477
Publication History
Submission date: 02 Jan 2023
Revised on: 06 Mar 2023
Accepted on: 12 Apr 2023
Published online: 14 Jul 2023
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.